• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对人类病毒组的血清学反应决定了意大利感染SARS-CoV-2患者的临床结局。

Serological Responses to Human Virome Define Clinical Outcomes of Italian Patients Infected with SARS-CoV-2.

作者信息

Wang Limin, Candia Julián, Ma Lichun, Zhao Yongmei, Imberti Luisa, Sottini Alessandra, Dobbs Kerry, Lisco Andrea, Sereti Irini, Su Helen C, Notarangelo Luigi D, Wang Xin Wei

机构信息

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892.

These authors contributed equally.

出版信息

medRxiv. 2020 Sep 7:2020.09.04.20187088. doi: 10.1101/2020.09.04.20187088.

DOI:10.1101/2020.09.04.20187088
PMID:32908997
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7480049/
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the pandemic respiratory infectious disease COVID-19. However, clinical manifestations and outcomes differ significantly among COVID-19 patients, ranging from asymptomatic to extremely severe, and it remains unclear what drives these disparities. Here, we studied 159 hospitalized Italian patients with pneumonia from the NIAID-NCI COVID-19 Consortium using a phage-display method to characterize circulating antibodies binding to 93,904 viral peptides encoded by 1,276 strains of human viruses. SARS-CoV-2 infection was associated with a marked increase in individual's immune memory antibody repertoires linked to trajectories of disease severity from the longitudinal analysis also including anti-spike protein antibodies. By applying a machine-learning-based strategy, we developed a viral exposure signature predictive of COVID-19-related disease severity linked to patient survival. These results provide a basis for understanding the roles of memory B-cell repertoires in COVID-19-related symptoms as well as a predictive tool for monitoring its clinical severity.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发了大流行性呼吸道传染病COVID-19。然而,COVID-19患者的临床表现和预后差异显著,从无症状到极其严重不等,目前尚不清楚导致这些差异的原因。在此,我们使用噬菌体展示方法,对美国国立过敏与传染病研究所-美国国立癌症研究所COVID-19联盟中159名住院的意大利肺炎患者进行了研究,以表征与1276株人类病毒编码的93904种病毒肽结合的循环抗体。通过纵向分析,包括抗刺突蛋白抗体,SARS-CoV-2感染与个体免疫记忆抗体库的显著增加有关,这些抗体库与疾病严重程度轨迹相关。通过应用基于机器学习的策略,我们开发了一种病毒暴露特征,可预测与COVID-19相关的疾病严重程度以及患者生存情况。这些结果为理解记忆B细胞库在COVID-19相关症状中的作用提供了基础,也为监测其临床严重程度提供了一种预测工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff42/7480049/5e7cd165ddef/nihpp-2020.09.04.20187088-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff42/7480049/260ab37c9fcf/nihpp-2020.09.04.20187088-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff42/7480049/2c5ff4b1bad1/nihpp-2020.09.04.20187088-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff42/7480049/796cd8e59438/nihpp-2020.09.04.20187088-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff42/7480049/5e7cd165ddef/nihpp-2020.09.04.20187088-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff42/7480049/260ab37c9fcf/nihpp-2020.09.04.20187088-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff42/7480049/2c5ff4b1bad1/nihpp-2020.09.04.20187088-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff42/7480049/796cd8e59438/nihpp-2020.09.04.20187088-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff42/7480049/5e7cd165ddef/nihpp-2020.09.04.20187088-f0004.jpg

相似文献

1
Serological Responses to Human Virome Define Clinical Outcomes of Italian Patients Infected with SARS-CoV-2.对人类病毒组的血清学反应决定了意大利感染SARS-CoV-2患者的临床结局。
medRxiv. 2020 Sep 7:2020.09.04.20187088. doi: 10.1101/2020.09.04.20187088.
2
Serological responses to human virome define clinical outcomes of Italian patients infected with SARS-CoV-2.人类病毒组的血清学反应定义了意大利感染 SARS-CoV-2 患者的临床结局。
Int J Biol Sci. 2022 Sep 1;18(15):5591-5606. doi: 10.7150/ijbs.78002. eCollection 2022.
3
Antibody tests for identification of current and past infection with SARS-CoV-2.抗体检测用于鉴定 SARS-CoV-2 的现症感染和既往感染。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
4
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
5
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原检测。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.
6
Measures implemented in the school setting to contain the COVID-19 pandemic.学校为控制 COVID-19 疫情而采取的措施。
Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029.
7
Physical interventions to interrupt or reduce the spread of respiratory viruses.物理干预措施以阻断或减少呼吸道病毒的传播。
Cochrane Database Syst Rev. 2023 Jan 30;1(1):CD006207. doi: 10.1002/14651858.CD006207.pub6.
8
Laboratory-based molecular test alternatives to RT-PCR for the diagnosis of SARS-CoV-2 infection.基于实验室的分子检测替代 RT-PCR 用于 SARS-CoV-2 感染的诊断。
Cochrane Database Syst Rev. 2024 Oct 14;10(10):CD015618. doi: 10.1002/14651858.CD015618.
9
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的 SARS-CoV-2 中和单克隆抗体。
Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
10
Sero-prevalence of SARS-CoV-2 antibodies in Ethiopia: Results of the National Population Based Survey, 2021.埃塞俄比亚2019冠状病毒病抗体血清流行率:2021年全国人口调查结果
PLoS One. 2025 May 6;20(5):e0313791. doi: 10.1371/journal.pone.0313791. eCollection 2025.

本文引用的文献

1
Sex differences in immune responses that underlie COVID-19 disease outcomes.COVID-19 疾病结局相关的免疫反应中的性别差异。
Nature. 2020 Dec;588(7837):315-320. doi: 10.1038/s41586-020-2700-3. Epub 2020 Aug 26.
2
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.SARS-CoV-2 反应性 T 细胞在健康供体和 COVID-19 患者中的研究。
Nature. 2020 Nov;587(7833):270-274. doi: 10.1038/s41586-020-2598-9. Epub 2020 Jul 29.
3
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications.
深度免疫剖析 COVID-19 患者,揭示具有治疗意义的不同免疫类型。
Science. 2020 Sep 4;369(6508). doi: 10.1126/science.abc8511. Epub 2020 Jul 15.
4
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.新型冠状病毒病 2019(COVID-19)的病理生理学、传播、诊断和治疗:综述。
JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839.
5
Genomewide Association Study of Severe Covid-19 with Respiratory Failure.全基因组关联研究严重新冠肺炎伴呼吸衰竭。
N Engl J Med. 2020 Oct 15;383(16):1522-1534. doi: 10.1056/NEJMoa2020283. Epub 2020 Jun 17.
6
Covid-19 and autoimmunity.新冠病毒与自身免疫
Autoimmun Rev. 2020 Aug;19(8):102597. doi: 10.1016/j.autrev.2020.102597. Epub 2020 Jun 11.
7
Considering how biological sex impacts immune responses and COVID-19 outcomes.考虑到生物性别如何影响免疫反应和 COVID-19 的结果。
Nat Rev Immunol. 2020 Jul;20(7):442-447. doi: 10.1038/s41577-020-0348-8. Epub 2020 Jun 11.
8
A Viral Exposure Signature Defines Early Onset of Hepatocellular Carcinoma.病毒暴露特征定义了肝细胞癌的早期发病。
Cell. 2020 Jul 23;182(2):317-328.e10. doi: 10.1016/j.cell.2020.05.038. Epub 2020 Jun 10.
9
Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses.SARS-CoV-2 和其他人类冠状病毒的致病性的基因组决定因素。
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15193-15199. doi: 10.1073/pnas.2008176117. Epub 2020 Jun 10.
10
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.在重症 COVID-19 患者中抑制布鲁顿酪氨酸激酶。
Sci Immunol. 2020 Jun 5;5(48). doi: 10.1126/sciimmunol.abd0110.